ResMed (RMD) PT Raised to $274 at KeyBanc; 'No Longer as Tariff-ied'
Tweet Send to a Friend
KeyBanc analyst Brett Fishbin raised the price target on ResMed (NYSE: RMD) to $274.00 (from $269.00) while maintaining a Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
